213 related articles for article (PubMed ID: 16645621)
1. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity.
Cheng WF; Lee CN; Su YN; Chai CY; Chang MC; Polo JM; Hung CF; Wu TC; Hsieh CY; Chen CA
Cancer Gene Ther; 2006 Sep; 13(9):873-85. PubMed ID: 16645621
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.
Cheng WF; Hung CF; Chai CY; Hsu KF; He L; Ling M; Wu TC
J Clin Invest; 2001 Sep; 108(5):669-78. PubMed ID: 11544272
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.
Cheng WF; Hung CF; Hsu KF; Chai CY; He L; Polo JM; Slater LA; Ling M; Wu TC
Hum Gene Ther; 2002 Mar; 13(4):553-68. PubMed ID: 11874633
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
[TBL] [Abstract][Full Text] [Related]
6. Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects.
Chen CA; Chang MC; Sun WZ; Chen YL; Chiang YC; Hsieh CY; Chen SM; Hsiao PN; Cheng WF
Gene Ther; 2009 Jun; 16(6):776-87. PubMed ID: 19357714
[TBL] [Abstract][Full Text] [Related]
7. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA.
Velders MP; McElhiney S; Cassetti MC; Eiben GL; Higgins T; Kovacs GR; Elmishad AG; Kast WM; Smith LR
Cancer Res; 2001 Nov; 61(21):7861-7. PubMed ID: 11691804
[TBL] [Abstract][Full Text] [Related]
8. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.
Liu B; Ye D; Song X; Zhao X; Yi L; Song J; Zhang Z; Zhao Q
Vaccine; 2008 Mar; 26(10):1387-96. PubMed ID: 18272260
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin.
Lin CT; Chang TC; Chao A; Dzeng E; Soong YK; Hung CF; Lai CH
J Biomed Sci; 2005; 12(2):279-87. PubMed ID: 15918000
[TBL] [Abstract][Full Text] [Related]
10. Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
Cheng WF; Lee CN; Chang MC; Su YN; Chen CA; Hsieh CY
Mol Ther; 2005 Nov; 12(5):960-8. PubMed ID: 15979942
[TBL] [Abstract][Full Text] [Related]
11. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
Cheng WF; Hung CF; Lee CN; Su YN; Chang MC; He L; Wu TC; Chen CA; Hsieh CY
Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037
[TBL] [Abstract][Full Text] [Related]
12. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis.
Cheng WF; Hung CF; Chen CA; Lee CN; Su YN; Chai CY; Boyd DA; Hsieh CY; Wu TC
Vaccine; 2005 May; 23(29):3864-74. PubMed ID: 15893626
[TBL] [Abstract][Full Text] [Related]
13. Gene gun administration of therapeutic HPV DNA vaccination restores the efficacy of prolonged defrosted viral based vaccine.
Lin CT; Yen CF; Shaw SW; Yen TC; Chen YJ; Soong YK; Lai CH
Vaccine; 2009 Dec; 27(52):7352-8. PubMed ID: 19781679
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Cheng WF; Hung CF; Hsu KF; Chai CY; He L; Ling M; Slater LA; Roden RB; Wu TC
Hum Gene Ther; 2001 Feb; 12(3):235-52. PubMed ID: 11177561
[TBL] [Abstract][Full Text] [Related]
15. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
Chen CH; Wang TL; Ji H; Hung CF; Pardoll DM; Cheng WF; Ling M; Wu TC
Gene Ther; 2001 Jan; 8(2):128-38. PubMed ID: 11313782
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of CD8 effector T cells by CD4 helper T cells eradicates growing tumors and promotes long-term tumor immunity.
Lin CT; Chang TC; Shaw SW; Cheng PJ; Huang CT; Chao A; Soong YK; Lai CH
Vaccine; 2006 Sep; 24(37-39):6199-207. PubMed ID: 16824651
[TBL] [Abstract][Full Text] [Related]
17. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
[TBL] [Abstract][Full Text] [Related]
18. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.
Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG
Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201
[TBL] [Abstract][Full Text] [Related]
19. CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination.
Cheng WF; Hung CF; Lin KY; Ling M; Juang J; He L; Lin CT; Wu TC
Gene Ther; 2003 Aug; 10(16):1311-20. PubMed ID: 12883527
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity.
Wang TL; Ling M; Shih IM; Pham T; Pai SI; Lu Z; Kurman RJ; Pardoll DM; Wu TC
Gene Ther; 2000 May; 7(9):726-33. PubMed ID: 10822298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
